Table of contents


Top

Editorial

So long to the silos p357

doi:10.1038/nbt.3544

Nature Biotechnology will now publish all computational biology papers in its research section, a decision that reflects an ongoing need to break down silos surrounding mathematical, computational and basic biology.


Exosome cancer diagnostic reaches market pp359 - 360

Cormac Sheridan

doi:10.1038/nbt0416-359


Illumina sues Oxford Nanopore p360

doi:10.1038/nbt0416-360


Roche bets on bromodomains pp361 - 362

Eva von Schaper

doi:10.1038/nbt0416-361


DNA writers attract investors pp363 - 364

Justin Petrone

doi:10.1038/nbt0416-363


Autism DNA hub opens p364

doi:10.1038/nbt0416-364


Biotech veteran wins Taiwan's presidential election pp365 - 366

David Cyranoski

doi:10.1038/nbt0416-365


India's budget windfall for biotech entrepreneurs p367

Killugudi Jayaraman

doi:10.1038/nbt0416-367


Paris—the city of 'bio'-light p368

doi:10.1038/nbt0416-368a


Around the world in a month p368

doi:10.1038/nbt0416-368b


News Feature

Will Europe toast GM wheat for gluten sufferers? pp369 - 371

Lucas Laursen

doi:10.1038/nbt.3533

Spanish researchers are testing GM low-gliadin wheat for gluten-allergy sufferers. But stifling EU bureaucracy and adoption challenges may mean an uphill struggle to market. Lucas Laursen investigates.


Top

Bioentrepreneur

Podcast

First Rounders Podcast: Daniel Cohen p372

doi:10.1038/nbt.3521


Data Page

Academic partnerships 2015 p372

Brady Huggett

doi:10.1038/nbt.3522


Top

Opinion and Comment

Correspondence

Ignore the Delaware director-compensation cases at your peril pp373 - 374

Doreen Lilienfeld, Brian Polovoy & Mark Kessel

doi:10.1038/nbt.3529


Compressive mapping for next-generation sequencing pp374 - 376

Deniz Yorukoglu, Yun William Yu, Jian Peng & Bonnie Berger

doi:10.1038/nbt.3511


Commentary

First, design for data sharing Open pp377 - 379

John Wilbanks & Stephen H Friend

doi:10.1038/nbt.3516

To upend current barriers to sharing clinical data and insights, we need a framework that not only accounts for choices made by trial participants but also qualifies researchers wishing to access and analyze the data.


Accessing the accelerated approval pathway for rare disease therapeutics pp380 - 383

Emil D Kakkis, Sara Kowalcyk & Max G Bronstein

doi:10.1038/nbt.3530

Improvements must be made to the qualification process for biomarkers as primary endpoints in pivotal clinical studies of treatments for the rarest of diseases.


Preparing for the next Zika pp384 - 386

Kendall Hoyt & Richard Hatchett

doi:10.1038/nbt.3532

Lessons from the US Biodefense program should inform international efforts to build a medical countermeasure enterprise for emerging infectious diseases.


Patents

Recent patents in epigenetic targeting p387

doi:10.1038/nbt.3549


Top

News and Views

Genome editing for clinical HIV isolates pp388 - 389

Michelle Kim & Robert F Siliciano

doi:10.1038/nbt.3531

An engineered recombinase removes the HIV-1 provirus from patient-derived cells and reduces infection in humanized mice.

See also: Research by Karpinski et al.


Receptor combinations hone T-cell therapy pp389 - 391

Thomas Blankenstein

doi:10.1038/nbt.3539

The safety of engineered T cells is improved through gated expression of two chimeric antigen receptors.


Plant immunity switched from bacteria to virus pp391 - 392

Artemis Giannakopoulou, Aleksandra Bialas, Sophien Kamoun & Vivianne G A A Vleeshouwers

doi:10.1038/nbt.3538

A plant immune receptor is engineered to recognize viruses rather than bacteria.


Research Highlights p392

doi:10.1038/nbt.3542


Top

Research

Perspective

Quality cell therapy manufacturing by design pp393 - 400

Yonatan Y Lipsitz, Nicholas E Timmins & Peter W Zandstra

doi:10.1038/nbt.3525


Article

Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity pp401 - 409

Janet Karpinski, Ilona Hauber, Jan Chemnitz, Carola Schäfer, Maciej Paszkowski-Rogacz, Deboyoti Chakraborty, Niklas Beschorner, Helga Hofmann-Sieber, Ulrike C Lange, Adam Grundhoff, Karl Hackmann, Evelin Schrock, Josephine Abi-Ghanem, M Teresa Pisabarro, Vineeth Surendranath, Axel Schambach, Christoph Lindner, Jan van Lunzen, Joachim Hauber & Frank Buchholz

doi:10.1038/nbt.3467

Excision of integrated HIV proviruses derived from most HIV-1 strains is achieved with a recombinase evolved in vitro.

See also: News and Views by Kim & Siliciano


Letters

Transcriptome-scale RNase-footprinting of RNA-protein complexes pp410 - 413

Zhe Ji, Ruisheng Song, Hailiang Huang, Aviv Regev & Kevin Struhl

doi:10.1038/nbt.3441

Transcriptome-scale detection of RNA regions protected by nonribosomal RNA-protein complexes.


An injectable nanoparticle generator enhances delivery of cancer therapeutics pp414 - 418

Rong Xu, Guodong Zhang, Junhua Mai, Xiaoyong Deng, Victor Segura-Ibarra, Suhong Wu, Jianliang Shen, Haoran Liu, Zhenhua Hu, Lingxiao Chen, Yi Huang, Eugene Koay, Yu Huang, Jun Liu, Joe E Ensor, Elvin Blanco, Xuewu Liu, Mauro Ferrari & Haifa Shen

doi:10.1038/nbt.3506

A silicon-based microparticle that delivers doxorubicin nanoparticles improves the efficacy of breast cancer chemotherapy.


High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines pp419 - 423

Channing Yu, Aristotle M Mannan, Griselda Metta Yvone, Kenneth N Ross, Yan-Ling Zhang, Melissa A Marton, Bradley R Taylor, Andrew Crenshaw, Joshua Z Gould, Pablo Tamayo, Barbara A Weir, Aviad Tsherniak, Bang Wong, Levi A Garraway, Alykhan F Shamji, Michelle A Palmer, Michael A Foley, Wendy Winckler, Stuart L Schreiber, Andrew L Kung & Todd R Golub

doi:10.1038/nbt.3460

A method called PRISM rapidly identifies drug candidates that are effective against specific cancer cell lines.


Targeted gene addition in human CD34+ hematopoietic cells for correction of X-linked chronic granulomatous disease pp424 - 429

Suk See De Ravin, Andreas Reik, Pei-Qi Liu, Linhong Li, Xiaolin Wu, Ling Su, Castle Raley, Narda Theobald, Uimook Choi, Alexander H Song, Andy Chan, Jocelynn R Pearl, David E Paschon, Janet Lee, Hannah Newcombe, Sherry Koontz, Colin Sweeney, David A Shivak, Kol A Zarember, Madhusudan V Peshwa, Philip D Gregory, Fyodor D Urnov & Harry L Malech

doi:10.1038/nbt.3513

Targeted genetic correction of hematopoietic stem cells is applied to X-linked chronic granulomatous disease.


Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy pp430 - 434

Lingfeng Liu, Daniel Sommermeyer, Alexandra Cabanov, Paula Kosasih, Tyler Hill & Stanley R Riddell

doi:10.1038/nbt.3461

Inclusion of a tag in CARs facilitates cell manipulation and downstream research studies.


One-step fermentative production of poly(lactate-co-glycolate) from carbohydrates in Escherichia coli pp435 - 440

So Young Choi, Si Jae Park, Won Jun Kim, Jung Eun Yang, Hyuk Lee, Jihoon Shin & Sang Yup Lee

doi:10.1038/nbt.3485

Application of a systems metabolic engineering strategy enables production of poly(lactate-co-glycolate) (PLGA) and other non-natural polymers in Escherichia coli.


Corrigendum

Corrigendum: Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease p441

James E Dahlman, Omar O Abudayyeh, Julia Joung, Jonathan S Gootenberg, Feng Zhang & Silvana Konermann

doi:10.1038/nbt0416-441a


Errata

Erratum: Phosphoproteomics takes it easy p441

Paola Picotti

doi:10.1038/nbt0416-441b


Erratum: Resequencing 302 wild and cultivated accessions identifies genes related to domestication and improvement in soybean p441

Zhengkui Zhou, Yu Jiang, Zheng Wang, Zhiheng Gou, Jun Lyu, Weiyu Li, Yanjun Yu, Liping Shu, Yingjun Zhao, Yanming Ma, Chao Fang, Yanting Shen, Tengfei Liu, Congcong Li, Qing Li, Mian Wu, Min Wang, Yunshuai Wu, Yang Dong, Wenting Wan, Xiao Wang, Zhaoli Ding, Yuedong Gao, Hui Xiang, Baoge Zhu, Suk-Ha Lee, Wen Wang & Zhixi Tian

doi:10.1038/nbt0416-441c


Top

Careers and Recruitment

Biomedical research workforce summit makes strides in implementing change for postdocs pp442 - 443

Viviane Callier

doi:10.1038/nbt.3537

Experts from industry and academia have begun the process of putting the biomedical research enterprise on a more sustainable path.


People

People p444

doi:10.1038/nbt.3548


Top